Diffusion Pharmaceuticals Inc.
DFFN
$0.41
Change (1 day)
$14.37
Year High
$4.14
Year Low
Categories
Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. Diffusion Pharmaceuticals Inc. was founded in 2001 and is based in Charlottesville, Virginia.
P/E ratio for Diffusion Pharmaceuticals Inc. (DFFN)
P/E ratio as of 2022: -1.02
According to Diffusion Pharmaceuticals Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.02. At the end of 2021 the company had a P/E ratio of -1.23.
P/E ratio history for Diffusion Pharmaceuticals Inc. from 1998 to 2022
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2022 | -1.02 |
| 2021 | -1.23 |
| 2020 | -3.02 |
| 2019 | -0.26 |
| 2018 | -0.53 |
| 2017 | -16.10 |
| 2016 | -1.92 |
| 2015 | -0.70 |
| 2014 | -0.63 |
| 2013 | -1.50 |
| 2012 | -0.08 |
| 2011 | -0.04 |
| 2010 | -0.05 |
| 2009 | -0.11 |
| 2008 | -0.32 |
| 2007 | -256.21 |
| 2006 | -0.70 |
| 2005 | 0.00 |
| 2004 | -3419.85 |
| 1999 | 0.00 |
| 1998 | 0.00 |